Skip to main content

Psoriatic arthritis

      RT @Stiddyo: #OP0223
      US disease activity and damage score for PsA - ~300 patients from 19 centres - 6 components for dis
      3 years 6 months ago
      #OP0223 US disease activity and damage score for PsA - ~300 patients from 19 centres - 6 components for disease activity score & 5 for damage -->~90% variability explained --> weighted score -->many sites to scan --> evaluation as BL pred. for MDA #EULAR2021 @RheumNow https://t.co/5kC6YDQi8D
      RT @Stiddyo: #OP0219
      Population based matched medical record database study in PsA vs. non PsA from Israel:
      -> no dif
      3 years 6 months ago
      #OP0219 Population based matched medical record database study in PsA vs. non PsA from Israel: -> no differences in mortality -> BL predictors of death -higher risk: higher age, male sex, prior hospitalisation, prior psoriasis, comorbidties -lower: csDMARDs #EULAR2021 #RheumNow
      RT @Janetbirdope: tyk2 makes sense to inhibit in PsA. Part of kinase family including JAK/TYK2, TYK2 is ⬆️in PsA. De
      3 years 6 months ago

      tyk2 makes sense to inhibit in PsA. Part of kinase family including JAK/TYK2, TYK2 is ⬆️in PsA. Deficiency of TYK2 gives less autoimmune diseases. @RheumNow @eular_org #EULAR2021 BMS Tyk Talk symposium https://t.co/knP9n0Qc0u

      RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb,
      3 years 6 months ago

      RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its faculty.

      EULAR 2021 - Day 2 Podcasts

      Check out this compilation of our EULAR 2021 Day 2 broadcasts below.

      You can also follow t
      3 years 6 months ago
      EULAR 2021 - Day 2 Podcasts Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud. https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
      New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptoTate )

      The evidence-based recommendat
      3 years 6 months ago
      New GRAPPA 2021 PsO and PsA Treatment Recommendations by Dr. Rachel Tate ( @uptoTate ) The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. Read more. https://t.co/AnHQGA8aKs https://t.co/yJbymc9csR
      RT @uptoTate: HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to r
      3 years 6 months ago
      HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to remain on csDMARDs.) This distinction may be explained by synthetic DMARDs on activity differences between the RA & PsA. Abstract #POS0633 #EULAR2021 https://t.co/VkkF28jm2f https://t.co/IkfGdZYNY3
      RT @uptoTate: Poster #POS0633 detailed HUR-BIO PsA pts started bDMARDs w/in 18 months of dx vs, on ave, 3x longer to sta
      3 years 6 months ago
      Poster #POS0633 detailed HUR-BIO PsA pts started bDMARDs w/in 18 months of dx vs, on ave, 3x longer to start bDMARDs in RA pts in real life data. What do you drugs do you start in your PsA pts after dx? Feel free to detail me below! #EULAR2021 @RheumNow
      ×